Skip to main content

Advertisement

Table 3 Treatment results by systemic chemotherapy and chemoradiotherapy

From: Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma

No. Sex Age Stage PS EGFR mutation status Initial treatment OR PFS (mos) OS (mos) Outcome
1 M 55 Relapsed 1 Wild DTX PD 0.7 7.3 Died
2 F 69 Relapsed 1 Exon 19 del Gefitinib CR 35.1 53.9 Died
3 M 60 Relapsed 1 Wild CBDCA + PTX PD 0.9 3.7 Died
4 F 45 Relapsed 0 Wild Gefitinib PD 1.7 10.7 Died
5 M 63 Relapsed 1 Wild CBDCA + PTX PD 0.6 12.7 Died
6 M 62 Relapsed 1 Wild CDDP + GEM PD 2.5 18.7 Died
7 F 53 Relapsed 2 Wild CBDCA + PTX PD 0.4 1 Died
8 F 55 Relapsed 1 Wild DTX PD 0.7 1.4 Died
9 M 56 Advanced 1 NA CBDCA + PTX PD 0.6 1.0 Died
10 M 77 Advanced 2 Wild CBDCA + ETP PD 1.5 7.2 Died
11 M 43 Advanced 1 Wild CBDCA + PTX SD 4.5 10.3 Died
12 M 62 Advanced 2 Wild CBDCA + PTX NE 0.4 0.4 Died
13 M 56 Relapsed 0 Wild CDDP + GEM NE 109.2 109.2 Alive
14 M 65 Stage IIIA 1 Wild CDDP + VNR + TRT PR 5.0 6.6 Died
15 F 66 Relapsed 1 Exon 21 L858R CDDP + VNR + TRT PR 3.9 6.9 Died
16 F 66 Stage IIIA 0 NA CDDP + VNR + TRT PR 65.4 65.4 Alive
  1. PS performance status, OR overall response, PFS progression-free survival, OS overall survival, DTX docetaxel, CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, GEM gemcitabine, ETP etoposide, VNR vinorelbine, TRT thoracic radiotherapy, SD stable disease, CR complete response, PD progressive disease, NE not evaluable, PR partial response